

**FILED**

**MAR 14 2008**

Judge Jamie D. Happas

**McCARTER & ENGLISH, LLP**  
Attorneys At Law  
Four Gateway Center  
100 Mulberry Street  
Newark, New Jersey 07102  
(973) 622-4444  
*Attorneys for Defendants AstraZeneca Pharmaceuticals LP  
AstraZeneca L.P*

---

IN RE : SUPERIOR COURT OF NEW JERSEY  
RISPERDAL/SEROQUEL/ZYPREXA : LAW DIVISION: MIDDLESEX COUNTY  
LITIGATION :  
: Case No 274  
: CIVIL ACTION  
:  
: CASE MANAGEMENT ORDER NO. 4B:  
: CONSENT ORDER AMENDING CASE  
: MANAGEMENT ORDER NO. 4, SECTIONS  
: I.A.(4), B.(4), and C.(4)

---

This matter initially having come before the Court at a Case Management Conference and the Court having entered Case Management No. 4 on August 3, 2007, regarding general discovery of the parties, Sections I. A(4), B.(4), and C. (4) of Case Management Order No. 4 specifically providing that plaintiff shall have until March 1, 2008 to serve written discovery upon defendants, and plaintiffs and defendants AstraZeneca Pharmaceuticals LP and related defendants ("AstraZeneca") Ortho-McNeil-Janssen Pharmaceuticals, Inc. (f/k/a Janssen Pharmaceutica Inc.) and related defendants ("OMJP, Inc."), and Eli Lilly and Company ("Lilly") and related defendants having agreed and stipulated to amendments of Sections I. A(4), B.(4), and C.(4) of Case Management Order No. 4 providing that plaintiffs shall have until August 1, 2008 to serve written discovery upon defendants, and for good cause shown;

*June 2, 2008 and/or*  
*as specified below as to each defendant*


IT IS ON THIS 14 day of March, 2008,

ORDERED that Section I. A.(4) of Case Management Order No. 4 is hereby amended to provide that plaintiffs shall be permitted to serve written discovery upon AstraZeneca at any time prior to August 1, 2008. AstraZeneca reserves the right to object to all or part of such written discovery on any grounds provided for under the New Jersey Rules of Court, including that the discovery sought is repetitive, redundant or cumulative of other discovery provided by AstraZeneca in this proceeding, in MDL 1769 and/or in any other related litigation. If such objections are made by AstraZeneca, AstraZeneca is required to identify, by Bates numbers and date produced, the documents produced or interrogatory responses that respond to the purportedly repetitive discovery in this litigation as part of its discovery.

IT IS FURTHER ORDERED that Section I. B.(4) of Case Management Order No. 4 is hereby amended to provide that plaintiffs shall be permitted to serve written discovery upon OMJP, Inc. at any time prior to June 2, 2008. OMJP, Inc. reserves the right to object to all or part of such written discovery on any grounds provided for under the New Jersey Rules of Court, including that the discovery sought is repetitive, redundant or cumulative of other discovery provided by OMJP, Inc. in this proceeding and/or in any other related litigation. If such objections are made by OMJP, Inc., OMJP, Inc. is required to identify, by Bates numbers and date produced, the documents produced or interrogatory responses that respond to the purportedly repetitive discovery in this litigation as part of its discovery.

IT IS FURTHER ORDERED that Section I. C.(4) of Case Management Order No. 4 is hereby amended to provide that to the extent Lilly employees have been deposed in MDL 1596 or in any other personal injury case regarding Zyprexa, they will not be redeposed in this action without leave of court and good cause shown. Plaintiffs shall be permitted to serve written discovery upon Lilly at any time prior to August 1, 2008. Lilly reserves the right to object to all

or part of such written discovery on any grounds provided for under the New Jersey Rules of Court, including that the discovery sought is repetitive, redundant or cumulative of other discovery provided by Lilly in this proceeding, in MDL 1596 and/or in any other related litigation. If such objections are made by Lilly, Lilly is required to identify, by Bates numbers and date produced, the documents produced or interrogatory responses that respond to the purportedly repetitive discovery in this litigation as part of its discovery.

  
\_\_\_\_\_  
Jamie D. Haggas, J.S.C.


I hereby consent to the form and entry hereof:

  
\_\_\_\_\_  
Weitz & Lydenberg  
Attorneys for Plaintiffs

I hereby consent to the form and entry hereof:

  
\_\_\_\_\_  
Shelter, P.C.  
Attorneys for Plaintiffs

I hereby consent to the form and entry hereof:

  
\_\_\_\_\_  
McCarter & English LLP  
Attorneys for AstraZeneca Pharmaceuticals LP and related defendants

I hereby consent to the form and entry hereof:



Drinker Biddle & Reath LLP  
Attorneys for Ortho-McNeil-Janssen Pharmaceuticals, Inc.  
(f/k/a Janssen Pharmaceutica Inc.) and related defendants

I hereby consent to the form and entry hereof:



Pepper Hamilton, LLP  
Attorneys for Eli Lilly and Company and related defendants